Drug Profile
Tenofovir alafenamide - Gilead Sciences
Alternative Names: GS-7340; GS-7340-02; GS-7340-03; TAF; Tenofovir alafenamide fumarate; VemlidyLatest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Developer Gilead Sciences; University Hospital Inselspital; University of California
- Class Amines; Antivirals; Phosphorus compounds; Propionates; Purines; Small molecules
- Mechanism of Action Nucleotide reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hepatitis B
- Phase III HIV-1 infections
- Phase II HIV infections
Most Recent Events
- 10 Nov 2023 Updated efficacy and adverse events data from a phase II trial in Hepatitis B presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
- 10 Nov 2023 Pooled efficacy data from phase III Study 108 and Study 110 trials in Hepatitis B presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AALSD-2023)
- 21 Jun 2023 Efficacy data from phase III trials (Study 108 and Study 110) in Hepatitis B presented at the European Association for the Study of the Liver Congress 2023 (EASL-2023)